BRCA1 and neoplasm: This is supported by findings of Silver and co-workers, who observed a better response to cisplatin in patients with TNBC when the BRCA1 promoter was hypermethylated, and hence, mRNA levels were lower in the tumor tissue compared with tumors without BRCA1 promoter methylation.